Strata Critical Medical shows standout revenue growth and a favorable engine-calculated risk/reward setup, but earnings quality red flags, a volatile earnings track record, and ongoing insider selling temper the bullish growth narrative.
Thesis pillars
- Strong Revenue Growth Industry Leader↑Improving
- Earnings Quality Red Flag↑Improving
- Favorable Risk Reward Asymmetry↑Improving
- +2 more pillars — see the Why tab for full reasoning
Strata Critical Medical, Inc. (SRTA) Stock Analysis
Inst Constrain edge
Healthcare · Medical Care Facilities
Sell if holding. Engine safety override at $5.97: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.50; Below-average business quality.
Strata Critical Medical (formerly Blade Air Mobility) is a time-critical logistics and clinical services provider to the U.S. transplant industry, operating one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement... Read more
Sell if holding. Engine safety override at $5.97: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.4/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-08-14Recent Developments — Strata Critical Medical, Inc.
Latest news
- NEWS Strata Critical Medical Reports Q2 2026 Results: Full Earnings Call Transcript — benzinga Aug 4, 2026 neutral
- NEWS Strata Critical Medical Q2 EPS $(0.12) Misses $(0.02) Estimate, Sales $72.506M Beat $67.112M Estimate — benzinga Aug 4, 2026 neutral
- NEWS Strata Critical Medical Raises FY2026 Sales Guidance from $260.000M-$275.000M to $285.000M-$295.000M vs $275.746M Est — benzinga Aug 4, 2026 positive
Generated 2026-08-14T12:42:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertransplant centers and OPOs10-K Item 1A: 'The transplant ecosystem in the United States is relatively concentrated among a limited number of transplant centers and OPOs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.97: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 2.4:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.55. Score 6.4/10, moderate confidence.
Take-profit target: $8.13 (+36.1% upside). Prior stop was $5.55. Stop-loss: $5.55.
Quality below floor (3.0 < 4.0).
Strata Critical Medical, Inc. trades at a P/E of N/A (forward N/A). TrendMatrix value score: 9.0/10. Verdict: Sell.
10 analysts cover SRTA with a consensus score of 4.2/5. Average price target: $10.
What does Strata Critical Medical, Inc. do?Strata Critical Medical (formerly Blade Air Mobility) is a time-critical logistics and clinical services provider to...
Strata Critical Medical (formerly Blade Air Mobility) is a time-critical logistics and clinical services provider to the U.S. transplant industry, operating one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations under the Trinity (Logistics) and Keystone (Clinical) brands. After divesting its legacy Passenger air mobility business to Joby Aero in August 2025 and acquiring Keystone in September 2025, the company now serves Medical Customers exclusively, making it more concentrated and less diversified than before.